ChoA Pharmaceutical Co.Ltd (034940) — Cash Flow-to-Debt Ratio

Latest as of December 2025: 0.00x

ChoA Pharmaceutical Co.Ltd (034940) has a Cash Flow-to-Debt Ratio of 0.00x as of December 2025, meaning its operating cash flow of ₩-143.53 Million could theoretically repay 0% of its total liabilities (₩42.92 Billion) in one year. See free cash flow generation of ChoA Pharmaceutical Co.Ltd to measure how efficiently the company converts operating cash flow to free cash.

CF-to-Debt Ratio

0.00x
Operating CF / Total Liabilities

Operating Cash Flow

₩-143.53 Million
KRW

Total Liabilities

₩42.92 Billion
KRW

Data as of

Dec 2025
Most recent filing

ChoA Pharmaceutical Co.Ltd Cash Flow-to-Debt Ratio (2004–2025)

Historical debt coverage capacity for ChoA Pharmaceutical Co.Ltd across 14 annual periods. Also explore 034940 shareholders equity momentum to track the company's year-over-year net asset growth rate.

Annual Cash Flow-to-Debt Ratio for ChoA Pharmaceutical Co.Ltd (2004–2025)

Year-by-year debt coverage analysis for ChoA Pharmaceutical Co.Ltd. For market capitalisation and broader financial context, see ChoA Pharmaceutical Co.Ltd market cap and net worth.

Year CF-to-Debt Ratio Operating CF (KRW) Total Liabilities YoY Change
2025 -0.10x ₩-4.18 Billion ₩42.92 Billion ▲ +12.9%
2024 -0.11x ₩-4.47 Billion ₩39.94 Billion ▼ -168.9%
2023 -0.04x ₩-1.48 Billion ₩35.46 Billion ▲ +5.5%
2022 -0.04x ₩-1.44 Billion ₩32.80 Billion ▲ +9.1%
2021 -0.05x ₩-1.48 Billion ₩30.59 Billion ▼ -160.6%
2020 0.08x ₩1.92 Billion ₩24.07 Billion ▼ -35.3%
2019 0.12x ₩4.16 Billion ₩33.69 Billion ▲ +81.5%
2018 0.07x ₩2.04 Billion ₩30.08 Billion ▲ +395.3%
2017 -0.02x ₩-675.51 Million ₩29.34 Billion ▼ -167.4%
2016 0.03x ₩930.42 Million ₩27.26 Billion ▼ -21.8%
2015 0.04x ₩1.19 Billion ₩27.19 Billion ▲ +95.1%
2014 0.02x ₩625.52 Million ₩27.96 Billion ▼ -87.2%
2013 0.17x ₩3.53 Billion ₩20.19 Billion ▲ +6.6%
2004 0.16x ₩3.57 Billion ₩21.78 Billion
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.